This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
by Zacks Equity Research
Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.
Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.
Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.
Mylan (MYL) Misses on Earnings and Sales Estimates in Q3
by Zacks Equity Research
Mylan (MYL) missed both earnings and sales estimates in the third quarter of 2017 as EpiPen sales continue to decline further.
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q3. Revenues also lag expectations considerably.
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) reported narrower-than-expected loss and missed sales estimates in the third-quarter 2017.
Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales
by Zacks Equity Research
Exelixis (EXEL) beat both earnings and sales estimates in the third quarter fueled by strong demand for Cabometyx for RCC.
Is a Beat in the Cards for Mylan (MYL) This Earnings Season?
by Zacks Equity Research
Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.
What's in the Cards for Prothena (PRTA) in Q3 Earnings?
by Zacks Equity Research
Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.
Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
by Zacks Equity Research
ImmunoGen's (IMGN) significant progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the company's third-quarter results.
What's in the Cards for Immune Design (IMDZ) in Q3 Earnings?
by Zacks Equity Research
Immune Design (IMDZ) will remain focused on the development of its key pipeline candidate's CMB305 and G100 in the third quarter of 2017.
What's in the Offing for Exelixis (EXEL) in Q3 Earnings?
by Zacks Equity Research
Exelixis, Inc. (EXEL) received a major boost with the FDA's approval of Cabometyx tablets and we expect investor focus on the drug's uptake when it reports third-quarter results.
Seattle Genetics (SGEN) Loss Narrows in Q3, Revenues Beat
by Zacks Equity Research
Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.
What to Expect From Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.
Top Research Reports for Lockheed Martin, 3M & T-Mobile
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Lockheed Martin (LMT), 3M (MMM), and T-Mobile (TMUS).
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.
Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength
by Zacks Equity Research
Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.
Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.
Roche (RHHBY) Reports Sales Numbers for First 9 Months
by Zacks Equity Research
Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
by Zacks Equity Research
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
by Zacks Equity Research
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
ImmunoGen to Push Leukemia Candidate into Phase I Trial
by Zacks Equity Research
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
by Zacks Equity Research
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
by Swarup Gupta
Foreign markets remain undeterred by discouraging events, notching up weekly gains.